个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Double-blinded, randomized clinical trial of Gegen Qinlian decoction pinpoints Faecalibacterium as key gut bacteria in alleviating hyperglycemia

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Gao Zezheng[1,2] * ; Zhang Wenhui[3,4] * ; He Lisha[5] * ; Wang Han[6] ; Li Yufei[7] ; Jiang Xiaotian[8] ; D I Sha[2] ; Wang Xinmiao[1] ; Zhang Xuan[9] ; Han Lin[1] ; Liu Yanwen[10] ; Gu Chengjuan[11] ; Wu Mengyi[12] ; He Xinhui[13] ; Cheng Lei[14] ; Wang Jun[3,4] ; Tong Xiaolin[1] ; Zhao Linhua[1] ;
机构： [1]Institute of Metabolic Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China. [2]Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China. [3]CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China. [4]University of Chinese Academy of Sciences, Beijing 100049, China. [5]Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. [6]School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China. [7]Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China. [8]Department of Endocrinology, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun 130000, China. [9]Biologicals Science and Technology Institute, Baotou Teacher's College, Baotou 014030, China. [10]Department of Endocrinology, Zhengzhou T.C.M. Hospital, Zhengzhou 450007, China. [11]Shenzhen Hospital, Guangzhou University of Chinese Medicine (Futian), Shenzhen 518000, China. [12]Department of Cardiology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China. [13]Department of Cardiology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming 650000, China. [14]Key Laboratory of Development and Application of Rural Renewable Energy, Biogas Institute of Ministry of Agriculture and Rural Affairs, Chengdu 610041, China.
出处：
DOI： 10.1093/pcmedi/pbae003
ISSN：

关键词： double-blinded randomized controlled trial type 2 diabetes mellitus Gegen Qinlian decoction Faecalibacterium metabolic disorders inflammation

摘要：
Accumulating evidence suggests that metabolic disorders, including type 2 diabetes mellitus (T2DM), can be treated with traditional Chinese medicine formulas, such as the Gegen Qinlian decoction (GQD). This study elucidates the mechanisms by which gut microbes mediate the anti-diabetic effects of GQD.We conducted a double-blind randomized clinical trial involving 120 untreated participants with T2DM. During the 12-week intervention, anthropometric measurements and diabetic traits were recorded every 4 weeks. Fecal microbiota and serum metabolites were measured before and after the intervention using 16S rDNA sequencing, liquid chromatography-mass spectrometry, and Bio-Plex panels.Anti-diabetic effects were observed in the GQD group in the human trial. Specifically, glycated hemoglobin, fasting plasma glucose, and two-hour postprandial blood glucose levels were significantly lower in the GQD group than in the placebo group. Additionally, Faecalibacterium was significantly enriched in the GQD group, and the short-chain fatty acid levels were higher and the serum inflammation-associated marker levels were lower in the GQD group compared to the placebo group. Moreover, Faecalibacterium abundance negatively correlated with the levels of serum hemoglobin, fasting plasma glucose, and pro-inflammatory cytokines. Finally, the diabetes-alleviating effect of Faecalibacterium was confirmed by oral administration of Faecalibacterium prausnitzii (DSMZ 17677) in T2DM mouse model.GQD improved type 2 diabetes primarily by modulating the abundance of Faecalibacterium in the gut microbiota, alleviating metabolic disorders and the inflammatory state.Registry No. ChiCTR-IOR-15006626.© The Author(s) 2024. Published by Oxford University Press on behalf of the West China School of Medicine & West China Hospital of Sichuan University.

基金：
This work was supported by the National Natural Science Foundation of China (Grants No. 81430097, 81973837, 82004242, 82274343 and 31771481) and the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (Grant No. ZYYCXTD-D-202001). The authors wish to thank Dr. Feng Tian for the advice on clinical data analysis.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 4 区 医学
小类 | 4 区 医学：研究与实验
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 医学：研究与实验
第一作者：
第一作者机构： [1]Institute of Metabolic Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China. [2]Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
共同第一作者：
通讯作者：
通讯机构： [3]CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China. [4]University of Chinese Academy of Sciences, Beijing 100049, China.
推荐引用方式(GB/T 7714)：
Gao Zezheng,Zhang Wenhui,He Lisha,et al.Double-blinded, randomized clinical trial of Gegen Qinlian decoction pinpoints Faecalibacterium as key gut bacteria in alleviating hyperglycemia[J].Precision Clinical Medicine.2024,7(1):pbae003.doi:10.1093/pcmedi/pbae003.
APA：
Gao Zezheng,Zhang Wenhui,He Lisha,Wang Han,Li Yufei...&Zhao Linhua.(2024).Double-blinded, randomized clinical trial of Gegen Qinlian decoction pinpoints Faecalibacterium as key gut bacteria in alleviating hyperglycemia.Precision Clinical Medicine,7,(1)
MLA：
Gao Zezheng,et al."Double-blinded, randomized clinical trial of Gegen Qinlian decoction pinpoints Faecalibacterium as key gut bacteria in alleviating hyperglycemia".Precision Clinical Medicine 7..1(2024):pbae003

相关文献

[1]Exploring the pathogenesis of type 2 diabetes mellitus intestinal damp-heat syndrome and the therapeutic effect of Gegen Qinlian Decoction from the perspective of exosomal miRNA. [2]A new method to evaluate the dose-effect relationship of a TCM formula Gegen Qinlian Decoction: "Focus" mode of integrated biomarkers. [3]Efficacy and safety of Gegen Qinlian decoction in the treatment of type II diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials [4]随机双盲临床对照试验中编盲及药物动态管理的规范化操作 [5]Efferocytosis: An Emerging Therapeutic Strategy for Type 2 Diabetes Mellitus and Diabetes Complications [6]Hyperoside Suppresses Renal Inflammation by Regulating Macrophage Polarization in Mice With Type 2 Diabetes Mellitus. [7]BIOSIMILAR BAT1406 VERSUS ADALIMUMAB THERAPY ON ACTIVE ANKYLOSING SPONDYLITIS: A RANDOMIZED, DOUBLE-BLINDED, MULTICENTER, CONTROLLED PHASE 3 TRIAL [8]Ruyi Zhenbao Pills for Patients with Motor and Sensory Dysfunction after Stroke: A Double-Blinded, Randomized Placebo-Controlled Clinical Trial [9]Effectiveness and safety of Xingbei Zhike granules in patients with postinfectious cough: A multicenter, randomized, double-blinded, placebo-controlled trial [10]Efficacy and Safety of Tongning Gel for Knee Osteoarthritis: A Multicentre, Randomized, Double-Blinded, Parallel, Placebo-Controlled, Clinical Trial.

资源点击量：2018 今日访问量：0 总访问量：645 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号